CH638562A5 - Process for obtaining a cleavage product of rabies virus - Google Patents
Process for obtaining a cleavage product of rabies virus Download PDFInfo
- Publication number
- CH638562A5 CH638562A5 CH170977A CH170977A CH638562A5 CH 638562 A5 CH638562 A5 CH 638562A5 CH 170977 A CH170977 A CH 170977A CH 170977 A CH170977 A CH 170977A CH 638562 A5 CH638562 A5 CH 638562A5
- Authority
- CH
- Switzerland
- Prior art keywords
- cleavage
- fraction
- rabies virus
- virus
- obtaining
- Prior art date
Links
- 238000003776 cleavage reaction Methods 0.000 title claims description 21
- 230000007017 scission Effects 0.000 title claims description 21
- 241000711798 Rabies lyssavirus Species 0.000 title claims description 14
- 238000000034 method Methods 0.000 title claims description 8
- 239000000047 product Substances 0.000 claims description 10
- 241000700605 Viruses Species 0.000 claims description 9
- 102000003886 Glycoproteins Human genes 0.000 claims description 8
- 108090000288 Glycoproteins Proteins 0.000 claims description 8
- 238000001155 isoelectric focusing Methods 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 5
- 239000002736 nonionic surfactant Substances 0.000 claims description 3
- 102000011931 Nucleoproteins Human genes 0.000 claims description 2
- 108010061100 Nucleoproteins Proteins 0.000 claims description 2
- 230000002163 immunogen Effects 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- XSXWOBXNYNULJG-UHFFFAOYSA-N 2-(2,4,4-trimethylpentan-2-yl)phenol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1O XSXWOBXNYNULJG-UHFFFAOYSA-N 0.000 claims 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 229920002113 octoxynol Polymers 0.000 claims 1
- 239000013504 Triton X-100 Substances 0.000 description 7
- 229920004890 Triton X-100 Polymers 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2605469A DE2605469C3 (de) | 1976-02-12 | 1976-02-12 | Verfahren zur Gewinnung eines Spaltprodukts des Tollwut-Virus und dieses enthaltender Impfstoff |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH638562A5 true CH638562A5 (en) | 1983-09-30 |
Family
ID=5969649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH170977A CH638562A5 (en) | 1976-02-12 | 1977-02-11 | Process for obtaining a cleavage product of rabies virus |
Country Status (15)
| Country | Link |
|---|---|
| JP (1) | JPS5299209A (https=) |
| AT (1) | AT350715B (https=) |
| BE (1) | BE851404A (https=) |
| CA (1) | CA1087982A (https=) |
| CH (1) | CH638562A5 (https=) |
| DE (1) | DE2605469C3 (https=) |
| DK (1) | DK145580C (https=) |
| FR (1) | FR2340955A1 (https=) |
| GB (1) | GB1567547A (https=) |
| IE (1) | IE44440B1 (https=) |
| IL (1) | IL51412A (https=) |
| IT (1) | IT1075115B (https=) |
| LU (1) | LU76737A1 (https=) |
| NL (1) | NL7701255A (https=) |
| OA (1) | OA05567A (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3070388D1 (en) * | 1980-10-02 | 1985-05-02 | Schering Corp | Injectable rabies vaccine composition and method for preparing same |
| MX2020004151A (es) | 2017-10-30 | 2020-08-13 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos. |
-
1976
- 1976-02-12 DE DE2605469A patent/DE2605469C3/de not_active Expired
-
1977
- 1977-02-03 FR FR7703023A patent/FR2340955A1/fr active Granted
- 1977-02-07 NL NL7701255A patent/NL7701255A/xx not_active Application Discontinuation
- 1977-02-10 GB GB5495/77A patent/GB1567547A/en not_active Expired
- 1977-02-10 LU LU76737A patent/LU76737A1/xx unknown
- 1977-02-10 IT IT20166/77A patent/IT1075115B/it active
- 1977-02-10 IL IL51412A patent/IL51412A/xx unknown
- 1977-02-10 OA OA56069A patent/OA05567A/xx unknown
- 1977-02-11 DK DK59377A patent/DK145580C/da active
- 1977-02-11 IE IE293/77A patent/IE44440B1/en unknown
- 1977-02-11 CA CA271,602A patent/CA1087982A/en not_active Expired
- 1977-02-11 AT AT92877A patent/AT350715B/de not_active IP Right Cessation
- 1977-02-11 CH CH170977A patent/CH638562A5/de not_active IP Right Cessation
- 1977-02-12 JP JP1353277A patent/JPS5299209A/ja active Pending
- 1977-02-14 BE BE174916A patent/BE851404A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK145580C (da) | 1983-05-16 |
| OA05567A (fr) | 1981-04-30 |
| ATA92877A (de) | 1978-11-15 |
| IT1075115B (it) | 1985-04-22 |
| BE851404A (fr) | 1977-08-16 |
| DK145580B (da) | 1982-12-13 |
| DE2605469A1 (de) | 1977-09-15 |
| GB1567547A (en) | 1980-05-14 |
| CA1087982A (en) | 1980-10-21 |
| DE2605469C3 (de) | 1980-04-10 |
| FR2340955B1 (https=) | 1979-03-02 |
| JPS5299209A (en) | 1977-08-19 |
| IE44440L (en) | 1977-08-12 |
| AT350715B (de) | 1979-06-11 |
| DE2605469B2 (de) | 1979-08-02 |
| IL51412A0 (en) | 1977-04-29 |
| FR2340955A1 (fr) | 1977-09-09 |
| DK59377A (da) | 1977-08-13 |
| IL51412A (en) | 1980-05-30 |
| NL7701255A (nl) | 1977-08-16 |
| LU76737A1 (https=) | 1977-08-19 |
| IE44440B1 (en) | 1981-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3001585C2 (de) | Verfahren zur Herstellung von Interferon Typ I und II | |
| DE3752165T2 (de) | Entfernung von fettlöslichen Reagenzien aus biologischen Materialien durch Extrahierung mit natürlichen Ölen oder synthetischen Ersätzen davon | |
| DE2854381A1 (de) | Verfahren zur gewinnung des antihaemophilen faktors viii aus blut, blutplasma oder blutplasma-fraktionen | |
| DE3014189A1 (de) | Verfahren zur herstellung eines immunogenen membranproteinaggregats von influenza-, parainfluenza- und rhabdo-viren | |
| US4421746A (en) | Process for producing interferon inducers | |
| DE3236126A1 (de) | Verfahren zur herstellung von zur intravenoesen verabreichung geeignetem (gamma)-globulin | |
| CH638562A5 (en) | Process for obtaining a cleavage product of rabies virus | |
| DE69133525T2 (de) | Verfahren zur Herstellung von recombinantem Hepatitis B Oberflächenantigen mit erhöhter Immunogen-Kapazität und Verwendung in einer Impfstoffzubereitung | |
| US5077202A (en) | Process for producing a glycolipid having a high eicosapentaenoic acid content | |
| DE2001902A1 (de) | Verfahren zur Anreicherung von Proteinen | |
| DD300833A7 (de) | Verfahren zur herstellung von inaktivierten influenza-vollvirusimpfstoffen | |
| DE2950004C2 (de) | Verfahren zur Herstellung von Frühsommer-Meningoenzephalitis-Virus(FSME-Virus)-Vakzinen | |
| US3436413A (en) | Process for the isolation of phosphatidyl serine | |
| DE2508396A1 (de) | Verfahren zur gewinnung von virusproteinen, die dabei erhaltenen proteine und diese proteine als wirkstoffe enthaltende arzneimittel | |
| IL39924A (en) | Hormone isolated from the parathyroid gland,its preparation and compositions containing it | |
| EP0315085B1 (de) | Rekombinantes histidinreiches Protein von Plasmodium falciparum, seine Herstellung und Verwendung | |
| DE2428955A1 (de) | Verfahren zur extraktion von bestandteilen mit in vivo antikoagulierender wirkung aus schlangengiften und daraus erhaltene produkte | |
| EP0322712B1 (de) | Malaria-spezifische DNA-Sequenzen, ihre Expressionsprodukte und deren Verwendung | |
| DE2447050A1 (de) | Verfahren zur gewinnung von proteasenhemmstoff | |
| DE3323093C2 (de) | Pharmazeutisches Präparat zur Bekämpfung von Tumoren | |
| US4495096A (en) | Process for producing and obtaining anaphylatoxin-and cocytotaxin-containing leucotaxine preparations and of anaphylatoxin and cocytotaxin proteins in molecularly homogeneous, biologically active form | |
| DE2333884A1 (de) | Verfahren zur herstellung von gereinigtem albumin und das dabei erhaltene gereinigte albumin | |
| EP0049424B1 (de) | Bioaktives, pflanzliche Wirkstoffe enthaltendes Mittel | |
| DD228737A1 (de) | Verfahren zur herstellung von influenza-inaktivimpfstoffen mit geringer stammabhaengigkeit | |
| DE3907162C2 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |